Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon, ...

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

Sanofi’s vaccine is designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis, which is responsible for the most common sexually transmitted ...